B. Diorio

588 total citations
7 papers, 24 citations indexed

About

B. Diorio is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, B. Diorio has authored 7 papers receiving a total of 24 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 6 papers in Oncology and 2 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in B. Diorio's work include Lung Cancer Treatments and Mutations (5 papers), Colorectal Cancer Treatments and Studies (2 papers) and Gastric Cancer Management and Outcomes (2 papers). B. Diorio is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Colorectal Cancer Treatments and Studies (2 papers) and Gastric Cancer Management and Outcomes (2 papers). B. Diorio collaborates with scholars based in United States, Spain and Canada. B. Diorio's co-authors include Raffaele Califano, Shalin Shah, Ryan D. Gentzler, Antonio Passaro, William N. William, Barbara Melosky, Joshua Bauml, Karen L. Reckamp, SH Lee and Yan Xu and has published in prestigious journals such as Annals of Oncology, Value in Health and ESMO Open.

In The Last Decade

B. Diorio

5 papers receiving 24 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
B. Diorio United States	3	21	20	8	4	3	7	24
Alice R.T. Bergin Australia	5	15 0.7×	15 0.8×	13 1.6×	3 0.8×	5 1.7×	8	41
José Fuentes Pradera Spain	4	33 1.6×	28 1.4×	5 0.6×	4 1.0×	4 1.3×	15	45
Haixin Huang China	4	20 1.0×	12 0.6×	8 1.0×	3 0.8×	4 1.3×	9	37
Jes Chauviere Lee United States	4	13 0.6×	16 0.8×	7 0.9×	2 0.5×	4 1.3×	8	28
Kunal Gawri United States	3	15 0.7×	17 0.8×	7 0.9×	2 0.5×	5 1.7×	9	25
Laura Leroy France	3	28 1.3×	18 0.9×	4 0.5×	5 1.3×	3 1.0×	8	36
Tongjian Cui China	4	25 1.2×	18 0.9×	11 1.4×	2 0.5×	1 0.3×	9	42
L. Paz-Ares Spain	2	13 0.6×	13 0.7×	4 0.5×	5 1.3×	3 1.0×	3	17
Pamela Cooper Australia	3	16 0.8×	13 0.7×	6 0.8×	2 0.5×	3 1.0×	6	27
Krishna Alluri United States	2	29 1.4×	10 0.5×	12 1.5×	2 0.5×	2 0.7×	3	36

Countries citing papers authored by B. Diorio

Since Specialization

Citations

This map shows the geographic impact of B. Diorio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. Diorio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. Diorio more than expected).

Fields of papers citing papers by B. Diorio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. Diorio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. Diorio. The network helps show where B. Diorio may publish in the future.

Co-authorship network of co-authors of B. Diorio

This figure shows the co-authorship network connecting the top 25 collaborators of B. Diorio. A scholar is included among the top collaborators of B. Diorio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. Diorio. B. Diorio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

Gardner, Mary, Jeffrey F. Peipert, Tanupriya Agrawal, et al.. (2024). PCR172 Patient-Reported Outcomes in Non-Small Cell Lung Cancer: Psychometric Evaluation of the PROMIS PF-SF 8C and NSCLC-SAQ in Phase 3 Clinical Trials. Value in Health. 27(6). S328–S328.

Califano, Raffaele, SH Lee, Yuzhuo Wang, et al.. (2024). LBA54 Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutated, advanced non-small cell lung cancer after disease progression on osimertinib: Second interim overall survival from MARIPOSA-2. Annals of Oncology. 35. S1244–S1245. 6 indexed citations

Gentzler, Ryan D., Alexander I. Spira, Barbara Melosky, et al.. (2024). 3MO Amivantamab plus chemotherapy vs chemotherapy in EGFR-mutant advanced NSCLC after progression on osimertinib: A post-progression analysis of MARIPOSA-2. ESMO Open. 9. 102582–102582. 2 indexed citations

Castro, Elena, Gerhardt Attard, Matthew R. Smith, et al.. (2023). LBA85 Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE. Annals of Oncology. 34. S1326–S1326. 6 indexed citations

Passaro, Antonio, Byoung Chul Cho, Yan Wang, et al.. (2023). LBA15 Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial. Annals of Oncology. 34. S1307–S1307. 8 indexed citations

Attard, G., Shahneen Sandhu, Dana E. Rathkopf, et al.. (2023). 1806P Efficacy of niraparib and abiraterone acetate plus prednisone (NIRA+AAP) in homologous recombination repair gene-altered (HRR+) metastatic castration-resistant prostate cancer (mCRPC) by tissue and/or plasma assays in the MAGNITUDE trial. Annals of Oncology. 34. S976–S977. 2 indexed citations

Lee, SH, Che Lin, Sandip Ganguly, et al.. (2023). LBA11 Amivantamab plus chemotherapy vs chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis. Annals of Oncology. 34. S1661–S1662.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact